Vishwas Setia
Fortuna: 13 M $ al 30/06/2026
Fortuna: 13 M $ al 30/06/2026
Vishwas Setia worked as an Investment Banking Summer Associate at Merrill Lynch & Co., Inc. in 2013.
Mr. Setia also worked as Chief Financial Officer at MapLight Therapeutics, Inc. from 2024 to 2026.
Mr. Setia completed an MBA degree at Kellogg School of Management in 2014 and holds an undergraduate degree from Delhi College of Engineering.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 06/05/2026 | 356.256 ( 0,84 % ) | 13 M $ | 30/06/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Director Financiero/CFO | 18/06/2026 |
Merrill Lynch & Co., Inc. /Old/
Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Corporate Officer/Principal | 01/08/2013 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Merrill Lynch & Co., Inc. /Old/
Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
Delhi College of Engineering
Delhi College of Engineering Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.